semaglutide and kidney function in patients with overweight or obesity chronic disease without diabetes: a randomized double-blind placebo-controlled clinical trial Effects of once-weekly subcutaneous semaglutide

It's a metabolic process

Sustaining Success: How to Manage Your Weight Loss Injections Need an extra boost of energy right away

Pharmacological GLP1-s work better and last longer than what your body produces on its own

The abdomen is often preferred by patients and healthcare providers due to its accessibility, consistent subcutaneous fat layer, and ease of self-administration

While adjustment for contributory factors or covariates attenuated the difference in the RH group, the small sample size limited the power of the analysis and conclusions that may be drawn are therefore limited

Real-world data from a 2025 study in Diabetes, Obesity and Metabolism which looked at actual clinical patients rather than trial participants showed tirzepatide patients lost 5.3% of body weight over six months compared to 2.7% with semaglutide